Unum Therapeutics to Present Pre-Clinical Data on its Antibody-Coupled T Cell Receptor (ACTR) Platform at the American Societ...
July 12 2018 - 7:00AM
Unum Therapeutics Inc. (NASDAQ:UMRX), a clinical-stage
biopharmaceutical company focused on the development of cellular
immunotherapies based on its novel, universal Antibody-Coupled T
cell Receptor (ACTR) technology platform, today announced that
the Company will be presenting pre-clinical data on the use of ACTR
T cells in combination with daratumumab, a CD38-specific antibody,
at the American Society of Hematology (ASH) Summit on Emerging
Immunotherapies for Hematological Diseases. The summit will take
place in Washington DC, later today.
CD38 is an antigen known to be expressed on tumor cells of
multiple myeloma, lymphoma, and AML patients. Unum has
demonstrated in pre-clinical studies that the combination of ACTR T
cells with daratumumab can drive potent activity against these
tumor cells. The Company is particularly interested in the
potential benefit that ACTR in combination with daratumumab can
provide in patients with AML.
“We believe that using a CD38-specific antibody to direct ACTR
attack has the potential to provide meaningful therapeutic benefit
to CD38 expressing malignancies, including AML patients for whom
treatment options continue to be very limited,” said Seth
Ettenberg, Unum’s Chief Scientific Officer. “We look forward to
bringing this novel approach into clinical testing in the
future.”
CD38 is a difficult antigen to target using conventional T cell
therapies, like CAR-T, because it is expressed on T cells.
Expression on T cells drives “fratricide” during manufacturing, a
process where activated T cells begin to attack and kill
themselves. Since ACTR T cells require a targeting antibody to be
activated and the targeting antibody is not present during
manufacturing, ACTR T cells can be manufactured without triggering
self-attack. As a result, ACTR has the potential to pursue T cell
targets like CD38.
Presentation Title: Adaptability of
Antibody-Coupled T Cell Receptor (ACTR) Engineered Autologous T
Cells in Combination with Daratumumab Over CAR-based Approaches
Presenter: Tooba Cheema, Principal Scientist, Unum
Therapeutics Presentation Date: Thursday, July 12,
2018 Presentation Time: 4:05 PM
Location: Omni Shoreham Hotel, Washington, DC
About Unum TherapeuticsUnum
Therapeutics is a clinical-stage biopharmaceutical company
focused on the development and commercialization of novel
immunotherapy products designed to harness the power of a patient’s
immune system to cure cancer. Unum’s novel proprietary technology,
Antibody-Coupled T cell Receptor (ACTR), is a universal, engineered
cell therapy intended to be used in combination with a wide range
of tumor-specific antibodies to target different tumor types.
ACTR087 used in combination with rituximab, an anti-CD20 antibody,
is Unum’s most advanced product candidate, currently in Phase I
clinical testing in adult patients with relapsed or refractory
non-Hodgkin lymphoma (r/r NHL). The Company has two additional
product candidates in Phase I clinical testing: ACTR087 used in
combination with the novel antibody SEA-BCMA in adult patients with
relapsed or refractory multiple myeloma and ACTR707, a modified
ACTR construct, used in combination with rituximab in adult
patients with r/r NHL. In addition, Unum expects to file an
investigational new drug application (IND) in 2018 for ACTR707 used
in combination with trastuzumab, an anti-human epidermal growth
factor receptor 2 (HER2) antibody, to treat patients with HER2+
cancers.
The Company is headquartered in Cambridge, MA.
Forward looking Statements
This press release contains forward-looking statements.
Statements in this press release about our future expectations,
plans and prospects, including projections regarding future
revenues and financing performance, our long-term growth, the
anticipated timing of our clinical trials and regulatory filings,
the development of our product candidates, including the four lead
ACTR product candidates, as well as other statements containing the
words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "might," "plan," "potential," "predict,"
"project," "should," "target," "will," or "would" and similar
expressions, constitute forward-looking statements within the
meaning of the safe harbor provisions of The Private Securities
Litigation Reform Act of 1995. We may not actually achieve the
forecasts disclosed in our forward-looking statements, and you
should not place undue reliance on our forward-looking statements.
Actual results could differ materially from the projections
disclosed in the forward-looking statements we make as a result of
a variety of risks and uncertainties, including risks related to
the accuracy of our estimates regarding expenses, future revenues,
capital requirements, and the need for additional financing, the
success, cost and timing of our product development activities and
clinical trials, our ability to obtain and maintain regulatory
approval for our product candidates, and the other risks and
uncertainties described in the "Risk Factors" sections of our
public filings with the Securities and Exchange Commission. In
addition, the forward-looking statements included in this press
release represent our views as of the date hereof. We anticipate
that subsequent events and developments may cause our views to
change. However, while we may elect to update these forward-looking
statements at some point in the future, we specifically disclaim
any obligation to do so. These forward-looking statements should
not be relied upon as representing our views as of any date
subsequent to the date hereof.
Investor Contact: Stern Investor Relations, Inc. Mary Conway,
212-362-1200 mary@sternir.com
Media Contact: Paul Kidwell,
617-680-1088paul.kidwell@unumrx.com
Unum Therapeutics (NASDAQ:UMRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Unum Therapeutics (NASDAQ:UMRX)
Historical Stock Chart
From Apr 2023 to Apr 2024